Palvella Therapeutics (PVLA) Stock Price, News & Analysis

Company Overview

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Key Stats

• Today's Range: $24.65 to $26.49
• 50-Day Range: $19.87 to $26.91
• 52-Week Range: $6.20 to $29.27
• Volume: 223,837 shs
• Average Volume: 70,759 shs
• Market Capitalization: $276.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.29
• Consensus Rating: Buy

Palvella Therapeutics Stock Analysis - MarketRank™

Palvella Therapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 191st out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Palvella Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Palvella Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Palvella Therapeutics are expected to grow in the coming year, from ($3.69) to ($2.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Palvella Therapeutics is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Palvella Therapeutics is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Palvella Therapeutics has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for PVLA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Palvella Therapeutics does not currently pay a dividend.

Dividend Growth

Palvella Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for PVLA.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.21

News Sentiment

Palvella Therapeutics has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Palvella Therapeutics this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for PVLA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Palvella Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,325.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

20.50% of the stock of Palvella Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.11% of the stock of Palvella Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PVLA Stock Analysis - Frequently Asked Questions

How have PVLA shares performed this year?

Palvella Therapeutics' stock was trading at $12.00 at the beginning of 2025. Since then, PVLA stock has increased by 108.8% and is now trading at $25.05.
View the best growth stocks for 2025 here.

How were Palvella Therapeutics' earnings last quarter?

Palvella Therapeutics (NASDAQ:PVLA) issued its quarterly earnings results on Thursday, May, 15th. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($3.40) by $2.66.
Read the conference call transcript.

Who are Palvella Therapeutics' major shareholders?

Palvella Therapeutics' top institutional investors include Frazier Life Sciences Management L.P. (6.25%), Millennium Management LLC (2.44%), Woodline Partners LP (1.76%) and Royce & Associates LP (0.65%).
View institutional ownership trends.

How do I buy shares of Palvella Therapeutics?

Shares of PVLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/15/2025
• Today: 6/14/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PVLA
• Previous Symbol: NASDAQ:PVLA
• CIK: 1583648
• Web: www.pieris.com
• Phone: 857-246-8998
• Fax: 49-8161-141-1444
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $46.29
• High Stock Price Target: $52.00
• Low Stock Price Target: $38.00
• Potential Upside/Downside: +84.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($12.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.54 million
• Net Margins: N/A
• Pretax Margin: -1,179.96%
• Return on Equity: -80.93%
• Return on Assets: -59.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.82
• Quick Ratio: 4.82

Sales & Book Value

• Annual Sales: $42.81 million
• Price / Sales: 6.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $21.66 per share
• Price / Book: 1.16

Miscellaneous

• Outstanding Shares: 11,056,000
• Free Float: 10,504,000
• Market Cap: $276.95 million
• Optionable: N/A
• Beta: -0.10